Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes
- 1 August 2016
- journal article
- Published by Springer Nature in Pharmacological Reports
- Vol. 68 (4) , 663-670
Abstract
5-Diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311), a promising antitumor agent that is also active against autoimmune diseases, was determined to be a selective inhibitor of the cytochrome P450 (CYP) 1A2 and 3A4 isoenzymes. Therefore, C-1311 might modulate the effectiveness of other drugs used in multidrug therapy. The present work aimed to identify the mechanism of the observed C-1311-mediated inactivation of CYP1A2 and CYP3A4. The inactivation experiments were performed in vitro using the human recombinant CYP1A2 and CYP3A4 (Bactosomes). CYP isoenzyme activities were determined using the CYP-specific reactions, 7-ethoxycoumarin O-deethylation (CYP1A2) and testosterone 6β-hydroxylation (CYP3A4). The concentrations of CYP-specific substrates and their metabolites formed by CYP isoenzymes were measured by RP-HPLC with UV-Vis detection. The inhibition of CYPs by C-1311 was time-, concentration- and NADPH-dependent, which suggested a mechanism-based mode of action. Using a 10-fold dilution method and potassium ferricyanide we demonstrated the irreversible nature of the inhibition. In addition, the inhibition was attenuated by the presence of alternate substrates (alternative active site ligands) but not by a nucleophilic trapping agent (glutathione) or a reactive oxygen scavenger (catalase), which further supported a mechanism-based action. Substrate depletion partition ratios of 299 and 985 were calculated for the inactivation of CYP1A2 and CYP3A4, respectively. Our results indicated that C-1311 is a potent mechanism-based inactivator of CYP1A2 and CYP3A4. This finding provided new insights into the mechanism of C-1311 antitumor action, particularly in relation to potential pharmacokinetic drug-–drug interactions between C-1311 and/or its derivatives and the substrates of CYP isoforms.Keywords
This publication has 32 references indexed in Scilit:
- The Imidazoacridinone Antitumor Drug, C-1311, Is Metabolized by Flavin Monooxygenases but Not by Cytochrome P450sDrug Metabolism and Disposition, 2011
- Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumoursEuropean Journal of Cancer, 2010
- Time‐dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressantsBritish Journal of Clinical Pharmacology, 2007
- Visible Spectra of Type II Cytochrome P450-Drug Complexes: Evidence that “Incomplete” Heme Coordination Is CommonDrug Metabolism and Disposition, 2007
- Inhibition of Cytochrome P450 3A4 by a Pyrimidineimidazole: Evidence for Complex Heme InteractionsChemical Research in Toxicology, 2006
- PREDICTION OF CYTOCHROME P450 3A INHIBITION BY VERAPAMIL ENANTIOMERS AND THEIR METABOLITESDrug Metabolism and Disposition, 2004
- Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylaminesXenobiotica, 2003
- Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolitesXenobiotica, 2002
- Structure−Activity Relationship for Antineoplastic Imidazoacridinones: Synthesis and Antileukemic Activity in VivoJournal of Medicinal Chemistry, 1996
- 5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activityJournal of Medicinal Chemistry, 1990